Targeting Oncogenic Drivers and the Immune System in Melanoma
- 1 February 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (4) , 499-506
- https://doi.org/10.1200/jco.2012.45.5568
Abstract
Melanoma is one of the most common cancers in Western countries but has defied the trend of reductions in age-adjusted mortality observed in most other cancers in recent years. Biologically, melano...This publication has 98 references indexed in Scilit:
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFPublished by Elsevier ,2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Increasing Burden of Melanoma in the United StatesJournal of Investigative Dermatology, 2009
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Mutations of the BRAF gene in human cancerNature, 2002